دورية أكاديمية
Seroprevalence of hepatitis C virus antigen in patients with chronic liver disease and hepatocellular carcinoma at 12 th week of treatment: a cross-sectional study.
| العنوان: | Seroprevalence of hepatitis C virus antigen in patients with chronic liver disease and hepatocellular carcinoma at 12 th week of treatment: a cross-sectional study. |
|---|---|
| المؤلفون: | Mbaga DS; Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon., Bikoï JN; Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon., Okobalemba EA; Faculty of Medicine and Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon., Essindi JO; Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon., Mikangue CAM; Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon., Membangbi AE; Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon., Ngoutane A; Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon.; Institute of Medical Research and Medicinal Plant Study, Yaoundé, Cameroon., Elang AF; Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon., Touangnou-Chamda SA; Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon., Sake CS; Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon., Mondinde GI; Faculty of Medicine and Biomedical Sciences, The University of Yaoundé I (Center for the Study and Control of Communicable Diseases (CSCCD), Yaoundé, Cameroon., Kenmoe S; Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon., Essama SHR; Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon. |
| المصدر: | The Pan African medical journal [Pan Afr Med J] 2022 Oct 11; Vol. 43, pp. 72. Date of Electronic Publication: 2022 Oct 11 (Print Publication: 2022). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: African Field Epidemiology Network Country of Publication: Uganda NLM ID: 101517926 Publication Model: eCollection Cited Medium: Internet ISSN: 1937-8688 (Electronic) NLM ISO Abbreviation: Pan Afr Med J Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Kampala, Uganda : African Field Epidemiology Network |
| مواضيع طبية MeSH: | Carcinoma, Hepatocellular*/epidemiology , Liver Neoplasms*/epidemiology , Hepatitis C*/epidemiology , Hepatitis C, Chronic*/epidemiology, Humans ; Hepacivirus ; Cross-Sectional Studies ; Seroepidemiologic Studies ; Cameroon ; Liver Cirrhosis/epidemiology ; Hepatitis C Antibodies |
| مستخلص: | Introduction: epidemiological data suggests that more than 50% of hepatitis C virus (HCV) patients fail treatment. The objective of the study was to highlight the seroprevalence of hepatitis C virus antigen (HCV Ag) at the 12 th week of treatment. Methods: during a cross-sectional study, participants with chronic liver disease and hepatocellular carcinoma (HCC) were recruited between December 2020 and March 2022 at the Yaoundé General Hospital (HGY) and the University Teaching Hospital of Yaounde (UTHY). Five millilitres of blood samples were taken from each consenting participant and then a qualitative search for HCV Ag by Enzyme-Linked Immuno Assay (ELISA) was performed. Analysis of the results was performed using SPSS Version 25.0 software. Results: out of the 192 participants selected for the study, only 92 (47,9%) participants were at 12 weeks of treatment, including 69 (75%) participants positive for the hepatitis C virus antibody (HCV Ab) by RDT. Of these participants, 44 (47.8%) participants were positive for HCV Ag by ELISA, respectively 19/37 (51.3%), 14/19 (73.6%), 11/13 (84.6%) with chronic hepatitis (HC), Cirrhosis, and HCC (P<0.0001). Conclusion: our results showed a high prevalence of HCV Ag in patients at their 12 th week of treatment which predicts treatment failure and calls for public policy to develop new management strategies to prevent HCV treatment failure in our context. Competing Interests: The authors declare no competing interests. (Copyright: Donatien Serge Mbaga et al.) |
| References: | Pan Afr Med J. 2019 Mar 15;32:122. (PMID: 31312290) Trop Med Infect Dis. 2021 Aug 10;6(3):. (PMID: 34449737) PLoS One. 2018 Apr 24;13(4):e0196301. (PMID: 29689073) BMJ Open. 2017 Aug 28;7(8):e015748. (PMID: 28851778) J Clin Exp Hepatol. 2019 Jan-Feb;9(1):4-12. (PMID: 30765933) Hepatology. 2010 Feb;51(2):415-21. (PMID: 19902424) Front Pharmacol. 2020 Nov 13;11:551500. (PMID: 33364936) Pan Afr Med J. 2019 Apr 29;32:212. (PMID: 31312324) New Microbiol. 2021 Apr;44(2):89-94. (PMID: 34151994) Chest. 2020 Jul;158(1S):S12-S20. (PMID: 32658647) J Gastroenterol Hepatol. 2021 Sep;36(9):2479-2485. (PMID: 33788314) Rom J Morphol Embryol. 2020 Oct-Dec;61(4):1185-1192. (PMID: 34171067) Cancer Prev Res (Phila). 2021 May;14(5):581-592. (PMID: 33608313) Clin Mol Hepatol. 2020 Jul;26(3):251-260. (PMID: 32188235) Hepatology. 2011 Nov;54(5):1547-58. (PMID: 22045672) PLoS One. 2022 Jan 21;17(1):e0262903. (PMID: 35061846) J Viral Hepat. 2017 Oct;24 Suppl 2:25-43. (PMID: 29105283) Clin Gastroenterol Hepatol. 2007 Dec;5(12):1462-8. (PMID: 18054753) BMC Infect Dis. 2018 Sep 14;18(1):461. (PMID: 30217169) Gut. 2013 May;62(5):766-73. (PMID: 22810757) J Viral Hepat. 2018 Aug;25(8):959-968. (PMID: 29533500) J Hepatol. 2020 Nov;73(5):1170-1218. (PMID: 32956768) Gastroenterol Hepatol (N Y). 2018 May;14(5):305-307. (PMID: 29991938) |
| فهرسة مساهمة: | Keywords: Hepatitis C virus Ag; chronic hepatitis; cirrhosis; hepatocellular carcinoma |
| المشرفين على المادة: | 0 (Hepatitis C Antibodies) |
| تواريخ الأحداث: | Date Created: 20230102 Date Completed: 20230103 Latest Revision: 20230111 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC9789782 |
| DOI: | 10.11604/pamj.2022.43.72.35450 |
| PMID: | 36590993 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1937-8688 |
|---|---|
| DOI: | 10.11604/pamj.2022.43.72.35450 |